After Launching Corporate Venture Fund, WuXi Shifts Attention To China’s Domestic Market: China Earnings Roundup (Part 2)
This article was originally published in PharmAsia News
China’s leading CRO grows revenues 24% in Q3, and establishes corporate venture fund to invest in homegrown innovation
You may also be interested in...
As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry
China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services